We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+18.21%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$9.8B
AUM Growth
+$1.86B
Cap. Flow
-$1.4B
Cap. Flow %
-14.24%
Top 10 Hldgs %
73.27%
Holding
123
New
14
Increased
15
Reduced
12
Closed
2

Top Buys

Rank Stock Value
1
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$247M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$188M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$112M
4
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$91.9M
5
SLXP
SALIX PHARMACEUTICALS LTD DEL
SLXP
+$75.9M

Top Sells

Rank Stock Value
1
PCYC
PHARMACYCLICS INC
PCYC
+$67.4M
2
XOMA
Xoma
XOMA
+$26.3M
3
AMBI
Ambit Biosciences Corp
AMBI
+$16.8M
4
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
+$14.3M
5
RPRX
Repros Therapeutics Inc.
RPRX
+$6.64M

Sector Composition

Rank Sector Weight
1 Healthcare 42.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FOMX
51
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$7.16M 0.07%
1,021,600
– –
CMRX
52
DELISTED
Chimerix, Inc.
CMRX
$6.94M 0.07%
+172,414
New +$5.84M
MTEM
53
DELISTED
Molecular Templates, Inc.
MTEM
$6.86M 0.07%
13,064
-16
-0.1% -$8K
ARRY
54
DELISTED
Array Biopharma Inc
ARRY
$6.78M 0.07%
1,433,797
– –
CNCE
55
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$6.73M 0.07%
505,418
+53,922
+12% +$696K
RARE icon
56
Ultragenyx Pharmaceutical
RARE
$2.5B
$6.58M 0.07%
150,000
– –
QLTI
57
DELISTED
QLT Inc
QLTI
$6.16M 0.06%
1,535,863
– –
IONS icon
58
Ionis Pharmaceuticals
IONS
$8.97B
$5.95M 0.06%
96,303
– –
STML
59
DELISTED
Stemline Therapeutics, Inc.
STML
$5.78M 0.06%
338,671
– –
ACHN
60
DELISTED
Achillion Pharmaceuticals
ACHN
$5.37M 0.05%
438,337
– –
IRWD icon
61
Ironwood Pharmaceuticals
IRWD
$598M
$5.3M 0.05%
413,315
– –
INFI
62
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$5.27M 0.05%
312,025
– –
JUNO
63
DELISTED
Juno Therapeutics, Inc.
JUNO
$5.22M 0.05%
+100,000
New +$4.48M
MNK
64
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$4.62M 0.05%
46,666
-155,190
-77% -$14.3M
ALDR
65
DELISTED
Alder Biopharmaceuticals
ALDR
$4.46M 0.05%
153,350
– –
WINT
66
DELISTED
Windtree Therapeutics Inc
WINT
$4.24M 0.04%
260,866
– –
FOLD
67
DELISTED
Amicus Therapeutics
FOLD
$4.01M 0.04%
481,697
– –
RXDX
68
DELISTED
Ignyta, Inc.
RXDX
$3.91M 0.04%
571,000
– –
LGND icon
69
Ligand Pharmaceuticals
LGND
$5.8B
$3.91M 0.04%
117,660
– –
ENTA icon
70
Enanta Pharmaceuticals
ENTA
$365M
$3.83M 0.04%
75,357
– –
EPZM
71
DELISTED
Epizyme, Inc
EPZM
$3.81M 0.04%
201,963
-12,049
-6% -$281K
CYTR
72
DELISTED
CytRx Corp
CYTR
$3.7M 0.04%
225,000
– –
KPTI icon
73
Karyopharm Therapeutics
KPTI
$156M
$3.52M 0.04%
6,273
– –
NDRM
74
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$3.51M 0.04%
+250,000
New +$1.98M
AKTX
75
Akari Therapeutics
AKTX
$14.5M
$3.23M 0.03%
84
– –
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q4 2014 Portfolio in Review

As of Q4 2014, Baker Bros. Advisors held 123 positions worth $9.8B, up 23% from $7.94B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Baker Bros. Advisors withdrew a net $1.4B in Q4 2014, closing 2 positions and reducing 12 holdings. Its most notable exit was Ambit Biosciences Corp, an estimated $16.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 42% of assets, up from 39% a quarter earlier.

Against the trend, Baker Bros. Advisors opened a new position in Bellicum Pharmaceuticals, Inc. worth $98.7M.

  • Baker Bros. Advisors's largest Q4 2014 buy was Bellicum Pharmaceuticals, Inc.: 428,373 shares worth $98.7M.
  • Baker Bros. Advisors added most to AVANIR PHARMACEUTICALS, INC CL A in Q4 2014, an estimated $247M increase.
  • Baker Bros. Advisors's biggest Q4 2014 reduction was PHARMACYCLICS INC, cutting an estimated $67.4M.
  • Baker Bros. Advisors fully exited Ambit Biosciences Corp in Q4 2014, selling an estimated $16.8M.
  • Baker Bros. Advisors's ten largest holdings make up 73% of its $9.8B portfolio in Q4 2014.
  • Baker Bros. Advisors opened 14 new positions and closed 2 in Q4 2014.
  • Baker Bros. Advisors's portfolio value rose 23% quarter-over-quarter to $9.8B.

Based on Baker Bros. Advisors's 13F filing for Q4 2014, filed 17 Feb 2015.